Erbitux Approved As Monotherapy In Metastatic Colorectal Cancer Setting
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for ImClone/Bristol’s epidermal growth factor receptor inhibitor is updated to include survival data as a single agent in colorectal cancer setting.
You may also be interested in...
Facing Flat Erbitux Sales, ImClone Talks Up Line Extension, Pipeline Promise
Firm details plans to become “global, fully integrated, pure play antibody company” during 2007 sales and earnings call.
Facing Flat Erbitux Sales, ImClone Talks Up Line Extension, Pipeline Promise
Firm details plans to become “global, fully integrated, pure play antibody company” during 2007 sales and earnings call.
KRAS Mutation Effective Biomarker For Vectibix Success, Amgen Reports
Biotech adds to industry KRAS buzz with biomarker analysis from its “408” study of the anti-EGFR comparing effectiveness against wild-type and mutated tumors.